Our research focuses on the potential use of modern technologies to improve detection of Leukaemia, to solve the ongoing problem of early detection, and to improve the medical industry through automation. Our first research project started in 2018 when Peter Moss was diagnosed with Acute Myeloid Leukemia (AML). With AML, there are no known warning signs, so early detection is very hard, if not impossible.
In Peter's case, the disease was completely missed in a standard blood test one month before being diagnosed as terminal. The Peter Moss Acute Myeloid & Lymphoblastic Leukaemia AI Research Project aimed to research into and develop open-source Artifical Intelligence with the goals of conquering the problem of early detection.
Peter Moss Leukaemia MedTech Research was formed to extend our research into other medical technologies, focusing on combining technologies such as Artificial Intelligence, the Internet of Things, the Blockchain, and Virtual/Augmented and Mixed Reality.